Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00144677 · ClinicalTrials.gov registry record · Phase 2
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
A Phase 2 study of Myelodysplastic Syndromes and Acute Lymphoblastic Leukemia, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00144677: Completed Phase 2 study of Myelodysplastic Syndromes and Acute Lymphoblastic Leukemia, sponsored by Dana-Farber Cancer Institute.
NCT00144677 is a Phase 2 study of Myelodysplastic Syndromes and Acute Lymphoblastic Leukemia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00144677, a Phase 2 study of Myelodysplastic Syndromes and Acute Lymphoblastic Leukemia, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from an unrelated donor. This trial is designed to test the hypothesis that elimination of methotrexate in the unrelated donor group would lead to less transplant-related toxicity while still preserving the effective control of GVHD.
Conditions Studied
Interventions
- DRUG tacrolimus
- DRUG sirolimus
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-11 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
What the finished NCT00144677 record still lists
NCT00144677 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (89% lower).
The record links to 7 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 2 interventions - of which tacrolimus is the first listed.
NCT00144677 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00144677 about?
NCT00144677 is a clinical study titled "Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation". The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from an unrelated donor. This trial is designed to test the hypothesis that elimination of methotrexate in the unrelated donor group would lead to ...
What is the current status of trial NCT00144677?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2003-11. Estimated completion is 2006-06.
What conditions does trial NCT00144677 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Graft-Versus-Host Disease, Acute Myelogenous Leukemia.
What interventions are being tested in trial NCT00144677?
The interventions under investigation include: tacrolimus (DRUG), sirolimus (DRUG).
Who is sponsoring clinical trial NCT00144677?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00144677 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00144677's enrollment target sits among peer trials
30 120th of 173 higher than 51 of 173 other Myelodysplastic Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Ascorbate in Myelodysplastic Syndrome
RECRUITING · Phase 2
-
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia